USA

The new site will complement RayzeBio’s existing 77,000-square-foot radiopharmaceutical manufacturing facility in Indianapolis, located about 20 miles southwest of Whitestown.

The two firms launched Metsera in 2022, and the biotech emerged from stealth in 2024 after securing US$290 million in financing.

McKesson expects the acquisition to strengthen its oncology and multi-specialty strategy while broadening the services it provides to biopharmaceutical companies.

Biohaven is currently evaluating the therapy in the Phase II/III RISE3 study, with results expected in the second half of 2026.

Over the past five years, the collaboration has supported more than 1,300 WellSpan patients across 12 cancer subspecialties through physician consultations, multidisciplinary tumour conferences and access to Johns Hopkins subspecialists.

As part of the agreement, Charles River will use technologies such as next-generation sequencing (NGS) to support chemistry, manufacturing and controls (CMC) activities associated with the vaccine programme.

By joining Lilly Gateway Labs, Rznomics plans to strengthen its drug discovery and development activities in the United States.

Construction of the Hillsboro facility is expected to create about 200 jobs, with workers remaining on site through the project’s anticipated completion in 2031.

The deal will give BioMarin access to ALE1, Alesta’s lead clinical-stage candidate for hypophosphatasia (HPP), a rare genetic bone disorder.

GM2 gangliosidoses are a group of rare inherited disorders that cause the progressive loss of nerve cells in the brain and spinal cord.